Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

arGEN-X files CTA for first-in-man ARGX-111 cancer study

Sep. 18, 2013

ISA initiates phase I/II trial in HIV-positive men with HPV16-positive AIN

Sep. 18, 2013

Affimed Therapeutics and the Leukemia & Lymphoma Society partner to advance AFM-13

Sep. 18, 2013

Bullet Biotechnology updates on financing and product development

Sep. 17, 2013

Ganymed obtains CE Mark for Claudetect 18.2 test

Sep. 17, 2013

FDA grants breakthrough therapy designation to ofatumumab for previously untreated CLL

Sep. 17, 2013

Janssen Biotech initiates phase II study of daratumumab in multiple myeloma

Sep. 13, 2013

EMA grants orphan drug designation to Patrys antibody for multiple myeloma

Sep. 12, 2013

FDA grants orphan status to ublituximab for two non-Hodgkin's lymphoma subtypes

Sep. 10, 2013

Gamida Cell reports transplantation of first patient in phase I/II study of NiCord in blood cancers

Sep. 10, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...